Clovis Oncology, Inc.
CLVSQ
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 30.66M | 32.14M | 34.25M | 35.97M | 37.92M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.66M | 32.14M | 34.25M | 35.97M | 37.92M |
| Cost of Revenue | 7.27M | 7.87M | 8.07M | 8.39M | 8.51M |
| Gross Profit | 23.40M | 24.27M | 26.18M | 27.58M | 29.41M |
| SG&A Expenses | 30.38M | 32.59M | 29.21M | 33.35M | 32.20M |
| Depreciation & Amortization | 1.34M | 1.34M | 1.34M | 1.34M | 1.34M |
| Other Operating Expenses | 5.12M | 13.29M | 3.73M | 3.49M | 3.84M |
| Total Operating Expenses | 74.90M | 91.52M | 84.61M | 88.38M | 92.11M |
| Operating Income | -44.24M | -59.38M | -50.36M | -52.41M | -54.19M |
| Income Before Tax | -55.98M | -71.37M | -60.29M | -64.67M | -67.40M |
| Income Tax Expenses | 35.00K | -41.00K | -120.00K | -279.00K | 13.00K |
| Earnings from Continuing Operations | -56.01M | -71.33M | -60.17M | -64.39M | -67.41M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.01M | -71.33M | -60.17M | -64.39M | -67.41M |
| EBIT | -44.24M | -59.38M | -50.36M | -52.41M | -54.19M |
| EBITDA | -42.35M | -57.48M | -48.44M | -50.41M | -52.17M |
| EPS Basic | -0.39 | -0.50 | -0.44 | -0.50 | -0.56 |
| Normalized Basic EPS | -0.24 | -0.31 | -0.27 | -0.30 | -0.33 |
| EPS Diluted | -0.39 | -0.50 | -0.44 | -0.50 | -0.56 |
| Normalized Diluted EPS | -0.24 | -0.31 | -0.27 | -0.30 | -0.33 |
| Average Basic Shares Outstanding | 144.63M | 144.04M | 138.21M | 128.47M | 121.22M |
| Average Diluted Shares Outstanding | 144.63M | 144.04M | 138.21M | 128.47M | 121.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
